1.Gonadotropin-releasing hormone antagonist protocol in patients with risk of poor response to ovarian stimulation in IVF-ET.
Journal of Zhejiang University. Medical sciences 2009;38(3):305-310
OBJECTIVETo evaluate the application of gonadotrophin-releasing hormone antagonist (GnRH-ant) in patients with risk of poor response to controlled ovarian stimulation in IVF-ET.
METHODSClinical data of 48 patients undergoing IVF with or without ICSI were retrospectively analyzed. Among them 24 patients were allocated to the GnRH-ant protocol and 24 to the long gonadotrophin-releasing hormone agonist (GnRH-a) protocol. The duration of down-regulation, duration of stimulation, amps of gonadotropin estradiol level on hCG day, number of oocytes retrieved, fertilization rate, total embryos obtained, high quality embryo obtained, embryos transferred, embryos frozen, implantation rate per transfer, clinical pregnancy rate per transfer, embryo survival rate, clinical pregnancy rate per frozen embryos transfer and per cycle were compared between two groups.
RESULTThe duration of down-regulation, duration of stimulation, the amps of gonadotropin were significantly lower in the antagonist group than those in agonist group (P <0.001, <0.05, <0.05), the estradiol level on hCG day, the number of oocytes retrieved were significantly lower in the antagonist group than those in the agonist group (P<0.05, <0.05). No significant differences were noted in fertilization rate, total embryos obtained, high quality embryo obtained, embryos transferred, embryos frozen, implantation rate per transfer, clinical pregnancy rate per transfer, embryo survival rate, clinical pregnancy rate per frozen embryos transfer and per cycle.
CONCLUSIONCompared with long GnRH-a protocol, the GnRH-ant protocol in patients with risk of poor response can reduce the dosage of gonadotropin and shorten the duration of stimulation, although the estradiol level on hCG day and the number of oocytes retrieved are lower, which does not affect the implantation rate and clinical pregnancy rate.
Adult ; Embryo Transfer ; Female ; Fertilization in Vitro ; Gonadotropin-Releasing Hormone ; agonists ; antagonists & inhibitors ; Hormone Antagonists ; pharmacology ; therapeutic use ; Humans ; Infertility, Female ; therapy ; Ovulation Induction ; methods ; Retrospective Studies
2.Glucocorticoid receptor and treatment of psychotic major depression.
Xin HUI ; Cai-hong ZHOU ; Ming-wei WANG
Acta Pharmaceutica Sinica 2005;40(11):961-966
Animals
;
Brain
;
metabolism
;
Dehydroepiandrosterone
;
therapeutic use
;
Depressive Disorder, Major
;
drug therapy
;
metabolism
;
physiopathology
;
Humans
;
Metyrapone
;
therapeutic use
;
Mifepristone
;
therapeutic use
;
Psychotic Disorders
;
drug therapy
;
metabolism
;
physiopathology
;
Pyrimidines
;
therapeutic use
;
Receptors, Corticotropin-Releasing Hormone
;
antagonists & inhibitors
;
Receptors, Glucocorticoid
;
antagonists & inhibitors
;
metabolism
3.Management of a patient with schizophrenia and underlying pituitary macroadenoma.
Kah Wee NG ; Jimmy LEE ; Verma SWAPNA
Annals of the Academy of Medicine, Singapore 2010;39(11):868-869
Adenoma
;
complications
;
pathology
;
Adult
;
Antipsychotic Agents
;
adverse effects
;
therapeutic use
;
Aripiprazole
;
Benzodiazepines
;
adverse effects
;
therapeutic use
;
Bromocriptine
;
adverse effects
;
therapeutic use
;
Dopamine Antagonists
;
adverse effects
;
therapeutic use
;
Female
;
Hormone Antagonists
;
adverse effects
;
therapeutic use
;
Humans
;
Hyperprolactinemia
;
complications
;
etiology
;
Piperazines
;
adverse effects
;
therapeutic use
;
Pituitary Neoplasms
;
complications
;
pathology
;
Quinolones
;
adverse effects
;
therapeutic use
;
Risperidone
;
adverse effects
;
therapeutic use
;
Schizophrenia
;
drug therapy
;
etiology
;
pathology
;
Serotonin Antagonists
;
adverse effects
;
therapeutic use
;
Trifluoperazine
;
adverse effects
;
therapeutic use
4.Cessation of Gonadotropin-Releasing Hormone Antagonist on Triggering Day: An Alternative Method for Flexible Multiple-Dose Protocol.
Hye Jin CHANG ; Jung Ryeol LEE ; Byung Chul JEE ; Chang Suk SUH ; Seok Hyun KIM
Journal of Korean Medical Science 2009;24(2):262-268
This study was performed to analyze retrospectively outcomes of stimulated in vitro fertilization (IVF) cycles where the gonadotropin-releasing hormone (GnRH) antagonist was omitted on ovulation triggering day. A total of 92 consecutive IVF cycles were included in 65 women who are undergoing ovarian stimulation with recombinant FSH. A GnRH antagonist, cetrorelix 0.25 mg/day, was started when leading follicle reached 14 mm in diameter until the day of hCG administration (Group A, 66 cycles) or until the day before hCG administration (Group B, 26 cycles). The duration of ovarian stimulation, total dose of gonadotropins, serum estradiol levels on hCG administration day, and the number of oocytes retrieved were not significantly different between the two groups. The total dose of GnRH antagonist was significantly lower in Group B compared to Group A (2.7+/-0.8 vs. 3.2+/-0.9 ampoules). There was no premature luteinization in the subjects. The proportion of mature oocytes (71.4% vs. 61.7%) and fertilization rate of mature (86.3+/-19.7% vs. 71.8+/-31.7%) was significantly higher in Group B. There were no significant differences in embryo quality and clinical pregnancy rates. Our results suggest that cessation of the GnRH antagonist on the day of hCG administration during a flexible multiple-dose protocol could reduce the total dose of GnRH antagonist without compromising IVF results.
Adult
;
Chorionic Gonadotropin/administration & dosage
;
Drug Administration Schedule
;
Estradiol/blood
;
Female
;
Fertilization in Vitro
;
Follicle Stimulating Hormone/administration & dosage/blood
;
Gonadotropin-Releasing Hormone/*antagonists & inhibitors
;
Hormone Antagonists/*administration & dosage
;
Humans
;
Ovulation Induction/*methods
;
Recombinant Proteins/therapeutic use
;
Retrospective Studies
5.Effect of GnRH antagonists on clinical pregnancy rates in ovulation induction protocols with gonadotropins and intrauterine insemination.
Ramazan DANSUK ; Ali Ihsan GONENC ; Sinem SUDOLMUS ; Oguz YUCEL ; Osman SEVKET ; Nadiye KÖROĞLU
Singapore medical journal 2015;56(6):353-356
INTRODUCTIONIntrauterine insemination (IUI) after controlled ovarian hyperstimulation (COH) was applied to selected infertile patients to determine the effect of gonadotropin-releasing hormone (GnRH) antagonists in IUI cycles, in which recombinant follicle-stimulating hormone (rFSH) had been used for COH.
METHODSThis study was conducted between April 1, 2009 and June 10, 2009, and involved a total of 108 patients. These patients had primary or secondary infertility, which resulted in an indication for IUI, and they each received two cycles of ovarian stimulation treatment with clomiphene citrate. The patients were randomised into two groups--patients in group A received rFSH + GnRH antagonist (n = 45), while those in group B received only rFSH (n = 63).
RESULTSThe mean age of the patients was 31.84 ± 3.73 years and the mean body mass index (BMI) was 24.40 ± 1.88 kg/m(2). The mean age and BMI of the patients in groups A and B were not significantly different. There was no significant difference in the mean total rFSH dose administered (988.33 IU in group A and 871.83 IU in group B). When compared to group B, the mean number of follicles that were > 16 mm on the human chorionic gonadotropin (HCG) trigger day was significantly higher in group A (1.58 and 1.86, respectively; p < 0.05). When the two groups were compared, there were no statistically significant differences in the number of cancelled cycles due to premature luteinisation (none in group A vs. two in group B) and the rate of clinical pregnancy (8.9% in group A vs. 7.9% in group B).
CONCLUSIONNo significant improvement in the clinical pregnancy rates was observed when GnRH antagonists were used in COH + IUI cycles, despite the significant increase in the number of follicles that were > 16 mm on HCG trigger day.
Adult ; Body Mass Index ; Chorionic Gonadotropin ; blood ; Clomiphene ; therapeutic use ; Endometrium ; pathology ; Female ; Follicle Stimulating Hormone ; therapeutic use ; Gonadotropin-Releasing Hormone ; antagonists & inhibitors ; Hormone Antagonists ; therapeutic use ; Humans ; Infertility, Female ; therapy ; Insemination, Artificial ; methods ; Ovulation Induction ; methods ; Pregnancy ; Pregnancy Rate ; Young Adult
6.Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
Rupesh RAINA ; Geetu PAHALAJANI ; Ashok AGARWAL ; Craig ZIPPE
Asian Journal of Andrology 2007;9(2):253-258
AIMTo evaluate the long-term effectiveness, side effects and compliance rates of two types of drugs (luteinizing hormone-releasing hormone [LHRH] agonist and antiandrogen) that were used individually to treat patients with localized prostate cancer (T1-2) at our institution.
METHODSNinety-seven patients who were diagnosed in the period from April 1997 to January 2000 as having clinically localized prostate cancer (T1-2) received either LHRH agonist (leuprolide acetate 7.5 mg/month) monotherapy (group 1, n = 62) or antiandrogen monotherapy (group 2, n = 35; 18 received bicalutamide 50 mg q.d., 13 received nilutamide 150 mg t.i.d. and 4 received flutamide 250 mg t.i.d.). The mean age in both groups was 76 years.
RESULTSThe mean follow-up time was (50.8 +/- 8.5) months in group 1 and (43.1 +/- 2.2) months in group 2. Prostate-specific antigen (PSA) levels rose in only 1 of the 62 patients (1.6%) in group 1, and in 20 of the 35 patients (57.1%) in group 2. In group 2, 10 of the 20 patients (50%) with increasing PSA levels were treated with LHRH salvage therapy, and eight (80%) responded. Hot flashes (54.8%) and lethargy (41.9%) were the most common side effects in group 1. In contrast, nipple-tenderness (40%) and light-dark adaptation (17.1%) were more often seen in group 2. Only 1 of the 62 patients (1.6%) in group 1 switched to another medication because of adverse side effects; whereas 8 of the 35 patients (22.9%) in group 2 did so.
CONCLUSIONUnlike antiandrogen monotherapy, LHRH agonist monotherapy provided long-term durable control of localized prostate cancer (T1-2). It can also be an effective treatment option for patients whose disease failed to respond to antiandrogen monotherapy. The limitations of our study are the lack of health outcomes analysis and a small sample size.
Aged ; Aged, 80 and over ; Androgen Antagonists ; adverse effects ; therapeutic use ; Anilides ; adverse effects ; therapeutic use ; Flutamide ; adverse effects ; therapeutic use ; Gonadotropin-Releasing Hormone ; agonists ; Humans ; Imidazolidines ; adverse effects ; therapeutic use ; Leuprolide ; adverse effects ; therapeutic use ; Male ; Nitriles ; adverse effects ; therapeutic use ; Prostate-Specific Antigen ; blood ; Prostatic Neoplasms ; drug therapy ; Retrospective Studies ; Tosyl Compounds ; adverse effects ; therapeutic use
7.Successful pregnancy following repeated implantation failure in patients with polycystic ovary syndrome: report of three cases.
Sisi YI ; Xin CHEN ; Yudong LIU ; Desheng YE ; Shiling CHEN
Journal of Southern Medical University 2014;34(9):1329-1333
We report 3 cases of polycystic ovary syndrome (PCOS) in which the patients had successful pregnancy after repeated implantation failure in at least 8 in vitro fertilization and embryo transfer (IVF-ET) cycles. The patients were treated with gonadotropin-releasing hormone antagonist (GnRH-ant) protocol and gonadotropin-releasing hormone angonist (GnRHa) for triggering ovulation, and successful pregnancy and normal deliveries were achieved after 9 IVT-ET cycles. For young patients with PCOS but a good ovarian reserve and a high ovarian response, treatment with GnRH antagonist protocol and GnRHa alone with appropriate management of the factors that may affect implantation can prevent severe ovarian hyperstimulation syndrome to achieve favorable clinical outcomes.
Embryo Implantation
;
Embryo Transfer
;
Female
;
Fertilization in Vitro
;
Gonadotropin-Releasing Hormone
;
agonists
;
antagonists & inhibitors
;
Gonadotropins
;
Hormone Antagonists
;
therapeutic use
;
Humans
;
Ovarian Hyperstimulation Syndrome
;
Ovulation
;
Ovulation Induction
;
Polycystic Ovary Syndrome
;
Pregnancy
;
Pregnancy Outcome
8.Hormone levels following surgical and medical castration: defining optimal androgen suppression.
Michael T SCHWEIZER ; Michael L HANCOCK ; Robert H GETZENBERG ; Evan Y YU
Asian Journal of Andrology 2018;20(4):405-406
Aged
;
Aged, 80 and over
;
Androgen Antagonists/pharmacology*
;
Androgens/blood*
;
Cohort Studies
;
Gonadotropin-Releasing Hormone/antagonists & inhibitors*
;
Hormones/blood*
;
Humans
;
Luteinizing Hormone/blood*
;
Male
;
Middle Aged
;
Orchiectomy
;
Prostatic Neoplasms/surgery*
;
Toremifene/therapeutic use*
9.High intensity focused ultrasound combined with endocrine therapy in treating prostate cancer.
Li-xin HUA ; Hong-fei WU ; Yuan-geng SUI ; Wei ZHANG ; Li-xin QIAN ; Ning-hong SONG ; Jie-xiu ZHANG
National Journal of Andrology 2005;11(3):195-197
OBJECTIVETo evaluate the clinical efficacy of high intensity focused ultrasound (HIFU) combined with endocrine therapy in the treatment of patients with prostate cancer.
METHODSTwenty patients with prostate cancer were treated with extracorporeal HIFU device( model FEP-BY01 ) and androgen ablation, of whom 15 received orchiectomy and 5 LHRH-a. Fourteen patients of the total number were given flutamide in addition to castration.
RESULTSThe mean follow-up was 13.5 months (ranging 6 to approximately 30). Before and after the treatment, the prostate volume, prostate specific antigen (PSA), international prostate symptom score (IPSS) and maximal flow rate (Qmax) of the patients were (36.4 +/- 16.2) ml and (20.6 +/- 11.8) ml (P < 0.05), (32.2 +/- 10.4) ng/ml and (2.4 +/- 0.8) ng/ml (P < 0.01), 20. 5 +/- 6.5 and 13.6 +/- 7.5 (P < 0.05), (10.6 +/- 6.3) ml/s and (14.2 +/- 4.6) ml/s (P < 0.05), respectively. Mild hematuria and pain were noted in 5 and 8 patients respectively, and 1 patient underwent internal urethrotomy with a cold knife because of urethral stricture. er, with minimal complications.
CONCLUSIONHIFU combined with endocrine therapy is effective in the treatment of prostate canc-
Aged ; Aged, 80 and over ; Antineoplastic Agents, Hormonal ; therapeutic use ; Combined Modality Therapy ; Flutamide ; therapeutic use ; Follow-Up Studies ; Gonadotropin-Releasing Hormone ; antagonists & inhibitors ; therapeutic use ; Humans ; Male ; Middle Aged ; Orchiectomy ; Prostatic Neoplasms ; therapy ; Treatment Outcome ; Ultrasound, High-Intensity Focused, Transrectal
10.Factors related to clinical pregnancy outcomes of in vitro fertilization-embryo transfer in women with secondary infertility.
Yi-feng LIU ; Xiao-qun YE ; Lin-ling ZHU ; Yun HUANG ; Yi-qing WU ; Peng XU ; Yu-jia KONG ; Feng LIU ; Sai-jun SUN ; Dan ZHANG
Journal of Zhejiang University. Medical sciences 2015;44(3):237-246
OBJECTIVETo investigate the factors related to clinical pregnancy outcomes of in vitro fertilization-embryo transfer (IVF-ET) in women with secondary infertility.
METHODSThe clinical, laboratory and follow-up data of 1129 cycles in 1099 patients with secondary infertility undergoing IVF-ET in Women's Hospital, Zhejiang University School of Medicine between July 2012 to July 2014 were retrospectively reviewed. The factors related to pregnancy outcomes were analyzed by univariate and logistic regression methods. The clinical pregnancy rates in women with different age and different number of embryos transferred were compared. The clinical outcomes of stimulation with gonadotropin releasing hormone (GnRH) agonist long protocol, GnRH agonist short protocol and GnH antagonist protocol were evaluated in secondary infertile patients aged ≥ 40 years.
RESULTSAmong 1129 cycles, 376 cases (33.30%) had clinical pregnancy and 753 cases (66.70%) had no clinical pregnancy. There were significant differences in age, body mass index, basal follicle-stimulating hormone level, antral follicle number,paternal age and number of embryos transferred between pregnancy and no pregnancy groups (P<0.05); while only maternal age (OR=0.900, 95% CI: 0.873~0.928, P<0.001) and the number of embryos transferred (OR=2.248, 95% CI: 1.906~2.652, P<0.001) were the independent factors affecting the clinical pregnancy outcome of IVF-ET. There was no significant difference in clinical pregnancy rate between women aged 30~40 years with two embryos transferred and those aged<30 years with two or three embryos transferred(P>0.05). There were no significances in clinical pregnancy rate among women aged ≥ 40 years using GnRH agonist long protocol,GnRH agonist short protocol and GnRH antagonist protocol for stimulation (P>0.05).
CONCLUSIONMaternal age and number of embryos transferred have independent effect on IVF-ET clinical pregnancy outcome of secondary infertile women. We suggest that no more than two embryos should be transferred for women in their thirties to minimize the risk of multiple pregnancy while still having an acceptable pregnancy rate. The pregnancy rate of patients over 40 years decreases significantly, and there is no difference in pregnancy rate by using GnRH agonist long protocol, GnRH agonist short protocol or GnRH antagonist protocol.
Adult ; Embryo Transfer ; Female ; Fertilization in Vitro ; Follicle Stimulating Hormone ; Gonadotropin-Releasing Hormone ; agonists ; Gonadotropins ; Hormone Antagonists ; therapeutic use ; Humans ; Infertility, Female ; Maternal Age ; Ovarian Follicle ; Ovulation Induction ; Pregnancy ; Pregnancy Outcome ; Pregnancy Rate ; Retrospective Studies